Methods of treating cancer using chemovirotherapy

Patent metadata

Field	Value
Publication number	US-9664684-B2
Application number	US-201113643962-A
Country	US
Kind code	B2
Filing date	Apr 29, 2011
Priority date	Apr 30, 2010
Publication date	May 30, 2017
Grant date	May 30, 2017

Abstract

Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.

First claim

The invention claimed is:

1. A method of treating cancer in a patient comprising
(a) exposing primary tumor cells of a pancreatic tumor sample obtained from a patient to different doses of (i) parvovirus H1 and (ii) GEMZAR (gemcitabine);
(b) determining the expression or concentration of ISG15 over varying time periods;
(c) identifying whether the expression or concentration of ISG15 has been reduced over the varying time periods which is indicative for the patient's sensitivity to chemovirotherapy;
(d) administering chemovirotherapy comprising parvovirus H1 and GEMZAR to a patient, wherein cancer is treated in the patient.

2. A method of treating cancer in a patient according to claim 1 , wherein the cancer is a or pancreatic cancer.

3. The method claim 1 , wherein the expression of ISG15 is determined on the mRNA level.

4. The method of claim 3 , wherein the mRNA level is determined by a hybridization based method or by PCR.

5. The method of claim 1 , wherein the concentration of ISG15 is determined using an antibody that specifically binds to ISG15.

6. The method claim 2 , wherein the expression of ISG15 is determined on the mRNA level.

7. The method of claim 6 , wherein the mRNA level is determined by a hybridization based method or by PCR.

8. The method of claim 2 , wherein the concentration of ISG15 is determined using an antibody that specifically binds to ISG15.

9. The method of treating cancer according to claim 1 , wherein the patient is a human.

10. The method of treating cancer according to claim 2 , wherein the patient is a human.

11. The method of treating cancer according to claim 1 , wherein administering is by a parenteral or enteral route.

12. The method of treating cancer according to claim 2 , wherein administering is by a parenteral or enteral route.

13. The method of treating cancer according to claim 1 , wherein parvovirus H1 and GEMZAR are administered to the patient separately.

14. The method of treating cancer according to claim 2 , wherein parvovirus H1 and GEMZAR are administered to the patient separately.

Assignees

• Giese Nathalia
• Werner Jens
• Buechler Markus
• Giese Thomas
• Daeffler Laurent
• Czeipluch Celina
• Rommelaere Jean
• Raykov Zahari
• Deutsches Krebsforsch
• Ruprecht-Karls-Universitaet Heidelberg
• Univ Heidelberg

Inventors

• Giese Nathalia
• Werner Jens
• Buechler Markus
• Giese Thomas
• Daeffler Laurent
• Czeipluch Celina
• Rommelaere Jean
• Raykov Zahari

Classifications

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/57484

  Physics · mapped topic

• G01N33/68 Primary

  involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title